Novartis, Switzerland Explore Gene Therapy Partnership with Algeria

Wassim Kouidri, the Algerian Minister of Pharmaceutical Industry, recently held discussions with Marion Weichelt, the Swiss Ambassador to Algeria, and a delegation from Novartis, a global leader in innovative medicines and gene therapies. The meeting, held at the Ministry's headquarters, focused on exploring avenues to strengthen cooperation and partnership between Algeria and Switzerland in the pharmaceutical sector. Novartis, recognized for its expertise in developing and producing innovative medicines, advanced biotechnologies, and gene therapies, presented an overview of its activities both in Algeria and internationally, highlighting its research and technological capabilities.

During the meeting, Minister Kouidri reiterated the sector's readiness to support economic operators keen on investing and expanding their activities within Algeria. This commitment aims to foster industrial partnerships, facilitate the transfer of advanced expertise and modern technologies, and ultimately enhance national capacities in medicine production and pharmaceutical industry development. The Minister also underscored the strategic importance of the Algerian Institute for Stem Cell Therapy project, currently overseen by the public group Saidal in collaboration with prominent foreign institutions. This national initiative is designed to introduce cutting-edge therapeutic technologies to Algeria, significantly improving patient care through the latest scientific and medical innovations.

Minister Kouidri emphasized the promising future offered by gene therapies for treating many severe diseases. Integrating these advanced technologies into the Institute's prospective services is expected to broaden access to modern treatments, thereby strengthening Algeria's national health sovereignty and elevating the standard of healthcare services available to its citizens. The Swiss Ambassador, Marion Weichelt, commended the robust bilateral relations between Algeria and Switzerland, particularly within the pharmaceutical domain, expressing Switzerland's interest in expanding cooperation through partnerships in innovative medicines, advanced therapeutic technologies, and the exchange of expertise and technology transfer.